The genome editing industry is growing rapidly and is expected to continue growing in the foreseeable future. According to a recent study, the global genome editing market size is projected to USD 11.7 billion by 2026 from USD 5.1 billion in 2021, at a CAGR of 18.2 % between 2021 and 2026. Recent developments in this field have led to significant improvements in the genome editing capabilities that have enabled the modification of gene sequences of interest in a wide variety of cell types and model organisms. Genome engineering, earlier used by large research organizations, such as academic and government research centers, has now become a potentially transformative diagnostic tool, especially for oncology studies. This shift from academics to clinical and diagnostic laboratories is primarily driven by rapid improvements in gene editing technologies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231037000
Innovation in Genome Editing Industry
The genome editing industry is an ever-evolving field of science, and there have been many advancements in the industry over the last few years. A few of the most notable advances include the development of CRISPR-Cas9 and TALEN gene editing technologies, the emergence of RNA-editing tools, and the use of directed evolution techniques. These advancements have enabled scientists and researchers to make precise edits to the genome, allowing for the development of new treatments for diseases. In addition, these technologies have been used to create transgenic plants and animals, and to develop methods for gene therapy.
In the near future, there is potential for further innovation in the genome editing industry. For example, scientists are developing new tools and techniques that allow for greater precision and accuracy when making genome edits. Additionally, researchers are exploring ways to use gene editing to create organisms with novel traits. Finally, there is potential to develop methods to edit the human genome safely and effectively, which could revolutionize the field of medicine.
Top Growing Segments in Genome Editing Industry
- CRISPR/Cas9 Genome Editing: CRISPR/Cas9 is a revolutionary gene-editing technology that has been widely adopted in the field of gene editing. This technology is being used to modify genomes in a variety of organisms, including plants, animals, and humans.
- TALENs Genome Editing: TALENs are a type of gene-editing technology that uses custom-engineered enzymes to alter specific sequences of DNA. This technology is being used to create genetically modified organisms and to conduct research on genetic diseases.
- Zinc Finger Nucleases (ZFNs) Genome Editing: ZFNs are a type of gene-editing technology that uses engineered proteins to modify specific sequences of DNA. This technology is being used to conduct research on genetic disorders and to modify genes in plants and animals.
- RNA-guided Genome Editing: RNA-guided genome editing is a powerful gene-editing technology that uses chemically modified RNA molecules to modify specific sequences of DNA. This technology is being used to study gene function and to create genetically modified organisms.
- Oligonucleotide-Based Genome Editing: Oligonucleotide-based genome editing is a gene-editing technology that uses short, synthetic DNA molecules to alter specific sequences of DNA. This technology is being used to study gene regulation and to create genetically modified organisms.
Some of the prominent key players are:
- Thermo Fisher Scientific Inc. (US),
- Merck KGaA (Germany),
- GenScript (China). and many others
Thermo Fisher Scientific (US) offers a complete and integrated portfolio of solutions and services for clinical science, laboratory research, and analysis. The company has a strong geographic footprint and operates in more than 150 countries across North America, Europe, Latin America, and Asia. The firm gained more than USD 12 billion in revenue in 2020 from its Life Sciences Solutions segment, which provides genome editing products and services. The company acquired Brammer Bio to increase its global presence in the market with the addition of their expertise in manufacturing vectors for genes and cell therapies. With its strong product portfolio, continuous research and development activities, and wide geographic reach, Thermo Fisher Scientific is expected to grow significantly in the global genome editing/ genome engineering market.
Merck KGaA (Germany) has gained a significant share in genome editing on account of its diversified product portfolio, widespread geographical presence, and focus on strategies such as agreements with other companies. Merck provides gene editing products through their research solutions subsegment of the Life Science segment. The company primarily focuses on inorganic strategies such as agreements.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=231037000
Based on the region, the genome editing/genome engineering market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA) regions. The market in Asia Pacific is to grow at the highest growth during the forecast period, primarily due to increasing investments in research and the rising number of applications of gene synthesis for genetic engineering of cells and tissues of organisms.
0
